Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D5084C00016
AstraZeneca AB
Healthy Volunteers
1 trial -
D533BC00003
AstraZeneca AB
Advanced solid tumour
1 trial -
D5985C00008
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D5985C00009
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D6830C00004
AstraZeneca AB
Asthma
1 trial -
D702EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D7260C00007
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
D740AC00001
AstraZeneca AB
Systemic Lupus Erythematosus, Rheumatoid Arthritis
1 trial -
D7860C00004
AstraZeneca AB
Chronic obstructive pulmonary disease
1 trial -
D7860C00005
AstraZeneca AB
Type 2 Diabetes Mellitus
1 trial -
D7930C00003
AstraZeneca AB
advanced liver fibrosis
1 trial -
D8210C00006
AstraZeneca AB
Asthma
1 trial -
D8330C00004
AstraZeneca AB
Heart failure with reduced ejection fraction, Renal impairment
1 trial -
D8340C00001
AstraZeneca AB
PLN R14del Dilated Cardiomyopathy
1 trial -
D8530C00001
AstraZeneca AB
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
1 trial -
D8990C00001
AstraZeneca AB
Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.
1 trial -
D8991C00002
AstraZeneca AB
Ovarian cancer Primary peritoneal cancer Fallopian tube cancer
1 trial -
D907HC00001
AstraZeneca AB
• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer
1 trial -
D9090C00007
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
D9090C00010
AstraZeneca AB
Impaired renal function
1 trial -
D9180C00006
AstraZeneca AB
Inflammation, Respiratory
1 trial -
D9180C00011
AstraZeneca AB
healthy volunteers
1 trial -
D926FC00001
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
D933IC00001
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.